Corcept Therapeutics | CORT - Selling And Administration Expenses


Corcept Therapeutics reported $128.04M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Alaunos Therapeutics USD 447K 138K Mar/2026
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Ardelyx USD 75.92M 7.69M Dec/2025
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Canopy Growth CAD 28.9M 636K Dec/2025
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
J&J USD 6.03B 719M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Merck USD 2.67B 180M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Novartis USD 3.44B 132M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 83.88M 7.99M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
TG Therapeutics USD 73.14M 22.42M Mar/2026